ZBH Stock Analysis — Zimmer Biomet
Sector: Healthcare
AI Verdict
Zimmer Biomet trades at 10.1x next year's earnings while analysts expect EPS to more than double, making it cheap for the growth you're getting if its entrenched hospital relationships keep driving procedure volumes.
Competitive Moat
Zimmer Biomet specializes in orthopedic implants and surgical tools, with a defensible position due to its deep relationships with hospitals and surgeons, plus regulatory barriers for new entrants. Its established distribution network and product breadth make it hard for competitors to displace in joint reconstruction and related procedures.
Summary
Zimmer Biomet is notable right now for its forecasted 126.2% jump in earnings per share over the next year.
Where It Stands
Zimmer Biomet has a 1-year return of -6.32%, an RSI of 46.7 indicating cooling momentum, and trades at 10.1x next year's earnings versus the healthcare sector median of 22x.
Key Metrics
- RSI: 46.7 — Neutral
- Trailing P/E: 22.7x
- Forward P/E: 10.1x
- PEG Ratio: 0.18
- Earnings Growth: +1.3%
- Revenue Growth: +0.1%
- Market Cap: $16.9B
- Dividend Yield: 0.01%
- 1-Year Return: -6.32%
- 52-Week High: $108.29
- 52-Week Low: $79.12
Analyst Consensus
12 Buy · 20 Hold · 2 Sell (34 analysts)
Bull Case
With forward EPS growth of 126.2% and a forward P/E of just 10.1x, you're getting rapid earnings growth at less than half the sector's typical multiple.
Bear Case
If the forward P/E rerates back up to the sector median of 22x, the stock could double, but if earnings disappoint, the current 22.7x trailing P/E could compress further, risking another leg down.
Catalyst to Watch
Watch for quarterly earnings to confirm that the massive EPS growth materializes — any miss could quickly erase the valuation discount.